Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine DOI Creative Commons
Jelena Dinić, Sofija Jovanović Stojanov, Miodrag Dragoj

et al.

Life, Journal Year: 2024, Volume and Issue: 14(9), P. 1142 - 1142

Published: Sept. 10, 2024

The field of oncology has witnessed remarkable progress in personalized cancer therapy. Functional precision medicine emerged as a promising avenue for achieving superior treatment outcomes by integrating omics profiling and sensitivity testing patient-derived cells. This review paper provides an in-depth analysis the evolution cancer-directed drugs, resistance mechanisms, role functional platforms revolutionizing individualized strategies. Using two-dimensional (2D) three-dimensional (3D) cell cultures, xenograft (PDX) models, advanced assays significantly improved our understanding tumor behavior drug response. will lead to identifying more effective treatments patients. Considering limited eligibility patients based on genome-targeted approach receiving targeted therapy, unprecedented opportunities customizing medical interventions according individual patient traits responses. delineates current landscape, explores limitations, presents future perspectives inspire ongoing advancements

Language: Английский

Human organoids-on-chips for biomedical research and applications DOI Creative Commons
Hui Wang,

Xiufan Ning,

Feng Zhao

et al.

Theranostics, Journal Year: 2024, Volume and Issue: 14(2), P. 788 - 818

Published: Jan. 1, 2024

Human organoids-on-chips (OrgOCs) are the synergism of human organoids (HOs) technology and microfluidic organs-on-chips (OOCs).OOCs can mimic extrinsic characteristics organs, such as environmental clues living tissue, while HOs more amenable to biological analysis genetic manipulation.By spatial cooperation, OrgOCs served 3D organotypic models allowing them recapitulate critical tissue-specific properties forecast responses outcomes.It represents a giant leap forward from regular 2D cell monolayers animal in improved ecological niche modeling.In recent years, have offered potential promises for clinical studies advanced preclinical-to-clinical translation medical industrial fields.In this review, we highlight cutting-edge achievements OrgOCs, introduce key features architectures, share revolutionary applications basic biology, disease modeling, preclinical assay precision medicine.Furthermore, discuss how combine wide range disciplines with accelerate translational applications, well challenges opportunities biomedical research applications.

Language: Английский

Citations

23
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method DOI Creative Commons
Qiushi Feng, Xiaofeng Shan, Vicky Yau

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(1), P. 62 - 62

Published: Jan. 8, 2025

Background: Tumors, as intricate ecosystems, comprise oncocytes and the highly dynamic tumor stroma. Tumor stroma, representing non-cancerous non-cellular composition of microenvironment (TME), plays a crucial role in oncogenesis progression, through its interactions with biological, chemical, mechanical signals. This review aims to analyze challenges stroma mimicry models, highlight advanced personalized co-culture approaches for recapitulating using patient-derived organoids (PDTOs). Methods: synthesizes findings from recent studies on composition, stromal remodeling, spatiotemporal heterogeneities TME. It explores popular stroma-related systems integrating PDTOs elements, techniques improve mimicry. Results: Stroma driven by cells, highlights dynamism heterogeneity PDTOs, derived tissues or cancer-specific stem accurately mimic tissue-specific genetic features primary tumors, making them valuable drug screening. Co-culture models combining elements effectively recreate TME, showing promise anti-cancer therapy. Advanced flexible combinations enhance precision tumor-stroma recapitulation. Conclusions: PDTO-based offer promising platform therapy development. underscores importance refining these advance medicine therapeutic outcomes.

Language: Английский

Citations

1
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance DOI Open Access

C. Raman Suri,

Babita Pande,

Lakkakula Suhasini Sahithi

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 8, 2025

Metabolic reprogramming within the tumor microenvironment (TME) plays a critical role in driving drug resistance gastrointestinal cancers (GI), particularly through pathways of fatty acid oxidation and glycolysis. Cancer cells often rewire their metabolism to sustain growth reshape TME, creating conditions such as nutrient depletion, hypoxia, acidity that impair antitumor immune responses. Immune TME also undergo metabolic alterations, frequently adopting immunosuppressive phenotypes promote progression reduce efficacy therapies. The competition for essential nutrients, glucose, between cancer compromises functions effector cells, T cells. Additionally, by-products like lactate kynurenine further suppress activity populations, including regulatory M2 macrophages. Targeting glycolysis presents new opportunities overcome improve therapeutic outcomes GI cancers. Modulating these key has potential reinvigorate exhausted shift toward phenotypes, enhance effectiveness immunotherapies other treatments. Future strategies will require continued research into metabolism, development novel inhibitors, clinical trials evaluating combination Identifying validating biomarkers be crucial patient stratification treatment monitoring. Insights may have broader implications across multiple types, offering avenues improving treatment.

Language: Английский

Citations

1
Experimental Murine Models for Colorectal Cancer Research DOI Open Access
Íris Neto, João Rocha, Maria Manuela Gaspar

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(9), P. 2570 - 2570

Published: April 30, 2023

Colorectal cancer (CRC) is the third most prevalent malignancy worldwide and in both sexes. Numerous animal models for CRC have been established to study its biology, namely carcinogen-induced (CIMs) genetically engineered mouse (GEMMs). CIMs are valuable assessing colitis-related carcinogenesis studying chemoprevention. On other hand, GEMMs proven be useful evaluating tumor microenvironment systemic immune responses, which contributed discovery of novel therapeutic approaches. Although metastatic disease can induced by orthotopic injection cell lines, resulting not representative full genetic diversity due limited number lines suitable this purpose. patient-derived xenografts (PDX) reliable preclinical drug development their ability retain pathological molecular characteristics. In review, authors discuss various murine with a focus on clinical relevance, benefits, drawbacks. From all discussed, will continue an important tool advancing our understanding treatment disease, but additional research required find model that correctly reflect pathophysiology CRC.

Language: Английский

Citations

14
Single-cell omics: a new perspective for early detection of pancreatic cancer? DOI
Wang Qi, Berina Šabanović,

Azhar Awada

et al.

European Journal of Cancer, Journal Year: 2023, Volume and Issue: 190, P. 112940 - 112940

Published: June 16, 2023

Language: Английский

Citations

7
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations DOI Open Access
Amber N. Habowski, Deepthi Poornima Budagavi, Sandra D. Scherer

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(3), P. 565 - 565

Published: Jan. 29, 2024

For over a century, early researchers sought to study biological organisms in laboratory setting, leading the generation of both vitro and vivo model systems. Patient-derived models cancer (PDMCs) have more recently come forefront preclinical are even finding their way into clinical practice as part functional precision medicine programs. The PDMC Consortium, supported by Division Cancer Biology National Institute Institutes Health, seeks understand principles that govern various behaviors, particularly response perturbagens, such therapeutics. Based on collective experience from consortium groups, we provide insight regarding PDMCs established vivo, with focus practical matters related developing maintaining key through series vignettes. Although every has potential offer valuable insights, choice right should be guided research question. However, recognizing inherent constraints each is crucial. Our objective here delineate strengths limitations individual Further advances development novel systems will enable us better human biology improve pathology lab.

Language: Английский

Citations

2
Potential Use of Organoids in Regenerative Medicine DOI
Wahyunia Likhayati Septiana, Jeanne Adiwinata Pawitan

Tissue Engineering and Regenerative Medicine, Journal Year: 2024, Volume and Issue: 21(8), P. 1125 - 1139

Published: Oct. 16, 2024

Language: Английский

Citations

2
Tumor Models and Drug Targeting In Vitro—Where Are We Today? Where Do We Go from Here? DOI Open Access
Marcus Krüger, Sascha Kopp

Cancers, Journal Year: 2023, Volume and Issue: 15(6), P. 1768 - 1768

Published: March 15, 2023

Cancer is one of the leading causes death worldwide [...].

Language: Английский

Citations

6
Organoid drug screening report for a non-small cell lung cancer patient with EGFR gene mutation negativity: A case report and review of the literature DOI Creative Commons

Yuetian Pan,

Hongshang Cui,

Yongbin Song

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: Feb. 16, 2023

Patients with non-small cell lung cancer (NSCLC) who carry epidermal growth factor receptor (EGFR) mutations can benefit significantly from EGFR tyrosine kinase inhibitors (EGFR TKIs). However, it is unclear whether patients without cannot these drugs. Patient-derived tumor organoids (PDOs) are reliable in vitro models that be used drug screening. In this paper, we report an Asian female NSCLC patient mutation. Her biopsy specimen was to establish PDOs. The treatment effect improved by anti-tumor therapy guided organoid

Language: Английский

Citations

5
Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine DOI Open Access
Yong Jae Shin,

Eun Hae Jo,

Yunjeong Oh

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(23), P. 5531 - 5531

Published: Nov. 22, 2023

Colorectal cancer is the third most common in world, with an annual incidence of 2 million cases. The success first-line chemotherapy plays a crucial role determining disease outcome. Therefore, there increasing demand for precision medicine to predict drug responses and optimize order increase patient survival reduce related side effects. Patient-derived organoids have become popular vitro screening model drug-response prediction medicine. However, no established correlation between oxaliplatin prediction. Here, we suggest that organoid culture conditions can resistance during screening, developed modified medium condition address this issue. Notably, while previous studies shown survivin mechanism resistance, our study observed consistent expression irrespective treatment. clusterin induced apoptosis inhibition cell survival, demonstrating significant resistance. This study's findings are expected contribute accuracy patient-derived APC mutant colorectal organoids, thereby providing reliable improving rates.

Language: Английский

Citations

4